- Home
- ADAG
ADAG
Adagene Inc.
as 12-17-2024 4:00pm EST
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
| Founded: | 2011 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 91.2M | IPO Year: | 2021 |
| Target Price: | $5.00 | AVG Volume (30 days): | 89.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.44 - $4.38 | Next Earning Date: | 07-25-2024 |
| Revenue: | $815,746 | Revenue Growth: | -96.40% |
| Revenue Growth (this year): | -47.91% | Revenue Growth (next year): | 2.70% |
Latest Adagene Inc. News
ADAG Breaking Stock News: Dive into ADAG Ticker-Specific Updates for Smart Investing
Zacks
12 days ago
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Simply Wall St.
19 days ago
November 2024's Top Picks: Penny Stocks On US Exchanges
Zacks
a month ago
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
GlobeNewswire
a month ago
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Simply Wall St.
2 months ago
Adagene And 2 Other US Penny Stocks To Consider
GlobeNewswire
2 months ago
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Zacks
3 months ago
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
GlobeNewswire
3 months ago
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Compare ADAG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADAG Adagene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.